Affordable Access

Publisher Website

The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping

Authors
Journal
The Breast
0960-9776
Publisher
Elsevier
Volume
23
Issue
3
Identifiers
DOI: 10.1016/j.breast.2014.02.013
Keywords
  • Breast Cancer
  • Androgen Receptor
  • Taxanes
  • Her2
  • Molecular Apocrine
  • Immunohistochemistry
Disciplines
  • Biology
  • Medicine

Abstract

Abstract Objectives The Androgen Receptor (AR) is a potential prognostic marker and therapeutic target in breast cancer. We evaluated AR protein expression in high-risk breast cancer treated in the adjuvant setting. Materials and methods Tumors were subtyped into luminal (ER+/PgR±/AR±), molecular apocrine (MAC, [ER−/PgR−/AR+]) and hormone receptor negative carcinomas (HR-negative, [ER−/PgR−/AR−]). Subtyping was evaluated with respect to prognosis and to taxane therapy. Results High histologic grade (p < 0.001) and increased proliferation (p = 0.001) more often appeared in MAC and HR-negative than in luminal tumors. Patients with MAC had outcome comparable to the luminal group, while patients with HR-negative disease had increased risk for relapse and death. MAC outcome was favorable upon taxane-containing treatment; this remained significant upon multivariate analysis for overall survival (HR 0.31, 95% CI 0.13–0.74, interaction p = 0.035) and as a trend for time to relapse (p = 0.15). Conclusion AR-related subtyping of breast cancer may be prognostic and serve for selecting optimal treatment combinations.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments